Portal de Periódicos da CAPES

Trends of Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region, 1984-2007

2011; Elsevier BV; Volume: 17; Issue: 9 Linguagem: Inglês

10.1016/j.bbmt.2011.01.019

1523-6536

Syed Osman Ahmed, Ardeshir Ghavamzadeh, Syed Ziauddin A. Zaidi, Helen Baldomero, Marcelo C. Pasquini, Fazal Hussain, Kamran Alimoghaddam, Fahad Almohareb, Mouhab Ayas, Amir Ali Hamidieh, Hossam K. Mahmoud, Alaa Elhaddad, Tarek Ben Othman, Abdelrahman Abdelkefi, Mahmoud Sarhan, Fawzi Abdel-Rahman, Salman Naseem Adil, Salam Alkindi, Ali Bazarbachi, Saïd Benchekroun, Dietger Niederwieser, Mary M. Horowitz, Aloïs Gratwohl, Hassan El Solh, Mahmoud Aljurf,

T-cell and B-cell Immunology

Hematopoietic stem cell transplantation (HSCT) activity was surveyed in the 9 countries in the World Health Organization Eastern Mediterranean region that reported transplantation activity. Between the years of 1984 and 2007, 7933 transplantations were performed. The number of HSCTs per year has continued to increase, with a plateau in allogeneic HSCT (allo-HSCT) between 2005 and 2007. Overall, a greater proportion of transplantations were allo-HSCT (n = 5761, 77%) compared with autologous HSCT (ASCT) (n = 2172, 23%). Of 5761 allo-HSCT, acute leukemia constituted the main indication (n = 2124, 37%). There was a significant proportion of allo-HSCT for bone marrow failures (n = 1001, 17%) and hemoglobinopathies (n = 885, 15%). The rate of unrelated donor transplantations remained low, with only 2 matched unrelated donor allo-HSCTs reported. One hundred umbilical cord blood transplantations were reported (0.017% of allo-HSCT). Peripheral blood stem cells were the main source of graft in allo-HSCT, and peripheral blood stem cells increasingly constitute the main source of hematopoietic stem cells overall. Reduced-intensity conditioning was utilized in 5.7% of allografts over the surveyed period. ASCT numbers continue to increase. There has been a shift in the indication for ASCT from acute leukemia to lymphoproliferative disorders (45%), followed by myeloma (26%). The survey reflects transplantation activity according to the unique health settings of this region. Notable differences in transplantation practices as reported to the European Group for Blood and Marrow Transplantation over recent years are highlighted.